Syndax Pharmaceuticals (SNDX) Accounts Payables (2015 - 2026)

Syndax Pharmaceuticals' Accounts Payables history runs 12 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 7.92% year-over-year to $10.8 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 7.92% increase from a year earlier, with the FY2025 full-year figure at $16.6 million, up 42.61% from the prior year.
• Accounts Payables fell to $10.8 million in Q1 2026 per SNDX's latest filing, from $16.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $17.4 million in Q2 2025 and bottomed at $4.4 million in Q4 2022.
• The 5-year median for Accounts Payables is $10.0 million (2023), against an average of $9.8 million.
• Across the five-year window, Accounts Payables slipped 23.27% in 2022 and surged 182.28% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $4.4 million in 2022, then soared by 128.99% to $10.0 million in 2023, then increased by 16.72% to $11.6 million in 2024, then surged by 42.61% to $16.6 million in 2025, then plunged by 34.6% to $10.8 million in 2026.
• Per Business Quant, the three latest SNDX Accounts Payables figures stand at $10.8 million (Q1 2026), $16.6 million (Q4 2025), and $13.8 million (Q3 2025).